Download File - JOHN J. HADDAD, Ph.D.

200 Chiang et al.
3. Willard HF, Angrist M, Ginsburg GS. Genomic medicine: genetic variation and its
impact on the future of health care. Philos Trans R Soc Lond B Biol Sci 2005;
360(1460):1543–1550.
4. Boyer CM, Borowitz MJ, McCarty KS Jr, et al. Heterogeneity of antigen expression
in benign and malignant breast and ovarian epithelial cells. Int J Cancer 1989; 43(1):
55–60.
5. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance
to tumor escape. Nat Immunol 2002; 3(11):991–998.
6. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine
development. Nat Rev Cancer 2002; 2(7):514–520.
7. Davis ID, Jefford M, Parente P, et al. Rational approaches to human cancer
immunotherapy. J Leukoc Biol 2003; 73(1):3–29.
8. Ward PL and Schreiber H. Tumor antigens recognized by T cells. Biological
approaches to cancer treatment. Biomodulation. pp. 72–97 (Mitchell, Ed.).
New York: McGraw Hill Inc. 1993.
9. York IA, Goldberg AL, Mo XY, et al. Proteolysis and class I major histocompatibility
complex antigen presentation. Immunol Rev 1999; 172:49–66.
10. Lankat-Buttgereit B, Tampé R. The transporter associated with antigen processing:
function and implications in human diseases. Physiol Rev 2002; 82(1):187–204.
11. Bouvier M. Accessory proteins and the assembly of human class I MHC molecules: a
molecular and structural perspective. Mol Immunol 2003; 39(12):697–706.
12. Momburg F, Tan P. Tapasin-the keystone of the loading complex optimizing peptide
binding by MHC class I molecules in the endoplasmic reticulum. Mol Immunol
2002; 39(3–4):217–233.
13. Hicklin DJ, Wang Z, Arienti F, et al. beta2-Microglobulin mutations, HLA class I
antigen loss, and tumor progression in melanoma. J Clin Invest 1998; 101(12):
2720–2729.
14. Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by
T lymphocytes. Annu Rev Immunol 1994; 12:337–365.
15. Rosenbery SA. Development of cancer immunotherapies based on identification of the
genes encoding cancer regression antigens. J Natl Cancer Inst 1996; 88(22): 1635–1644.
16. Benitez R, Godelaine D, Lopez-Nevot MA, et al. Mutations of the beta2-microglobulin
gene result in a lack of HLA class I molecules on melanoma cells of two
patients immunized with MAGE peptides. Tissue Antigens 1998; 52(6):520–529.
17. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and
tumor growth. Immunol Today 2000; 21(9):455–464.
18. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that
influence tumor regression/progression. Cancer Immunol Immunother 2004; 53(10):
844–854.
19. van Duinen SG, Ruiter DJ, Broecker EB, et al. Level of HLA antigens in locoregional
metastases and clinical course of the disease in patients with melanoma.
Cancer Res 1988; 48(4):1019–1025.
20. Restifo NP, Marincola FM, Kawakami Y, et al. Loss of functional beta 2-microglobulin
in metastatic melanomas from five patients receiving immunotherapy.
J Natl Cancer Inst 1996; 88(2):100–108.
21. Jäger E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo: independent
loss of MHC class I and melanocyte differentiation antigen expression in
metastatic melanoma. Int J Cancer 1997; 71(2):142–147.